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ABSTRACT
Adiponectin, which plays a pivotal role in metabolic liver diseases, is reduced in concentration
in patients with NASH (non-alcoholic steatohepatitis). The aim of the present study was to
determine adiponectin concentrations in patients with different forms and stages of chronic
liver diseases. Serum adiponectin concentrations were measured in 232 fasting patients with
chronic liver disease: 64 with NAFLD (non-alcoholic fatty liver disease), 123 with other chronic
liver disease (e.g. viral hepatitis, n=71; autoimmune disease, n=18; alcohol-induced liver
disease, n=3; or elevated liver enzymes of unknown origin, n=31) and 45 with cirrhosis.
Circulating adiponectin levels were signiﬁcantly lower in patients with NAFLD in comparison with
patients with other chronic liver disease (4.8+ −3.5 compared with 10.4+ −6.3 μg/ml respectively;
P<0.0001). Circulating adiponectin levels were signiﬁcantly higher in patients with cirrhosis
in comparison with patients without cirrhosis (18.6+ −14.5 compared with 8.4+ −6.1 μg/ml
respectively; P<0.0001). Adiponectin concentrations correlated negatively with body weight
(P<0.001), serum triacylglycerols (triglycerides) (P<0.001) and, in women, with BMI (body
mass index) (P<0.001). Adiponectin concentrations correlated positively with serum bile acids
(P<0.001), serum hyaluronic acid (P<0.001) and elastography values (P<0.001). Adiponectin
levelsweredecreasedinpatientswithNAFLD.Inconclusion,adiponectinlevelscorrelatepositively
with surrogate markers of hepatic ﬁbrosis (transient elastography, fasting serum bile acids and
hyaluronate) and are signiﬁcantly elevated in cases of cirrhosis.
INTRODUCTION
Adiponectin is a 244-amino-acid adipocytokine that
plays a pivotal role in metabolic liver diseases. Adipo-
nectin is produced by adipocytes [1,2] and circulates
at high concentrations (0.5–30 μg/ml) in plasma under
normal physiological conditions. Adiponectin levels
are hormonally regulated: the hormone testosterone
inhibits adiponectin secretion, triggering lower levels of
adiponectin in men [3]. In the liver, adiponectin increases
fatty acid β-oxidation, thereby decreasing hepatic TG
[triacylglycerol(triglyceride)]contentandhepaticinsulin
resistance. Adiponectin-associated metabolic effects are
exerted via corresponding receptors, AdipoR1 (adipo-
nectin receptor 1) and AdipoR2 (adiponectin receptor
2). Although AdipoR1 is considered important for
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mediatingadiponectineffectsinskeletalmuscle,AdipoR2
appears to be the predominant player in liver [4,5].
Adiponectin plasma levels correlate negatively with
BMI (body mass index) and body fat mass, and fasting
plasma glucose, insulin and TG levels [1,2,6,7]. Patients
withNASH (non-alcoholicsteatohepatitis)have reduced
circulating adiponectin levels [5,8–10]. The ease with
which the levels of adiponectin can be measured, owing
to its high abundance, small diurnal variation and high
stability in plasma, has made it an attractive target
for measurements in clinical settings. It has emerged
as a valuable biomarker to monitor insulin sensitivity,
cardiovascular risk and inﬂammation; however, its
signiﬁcance in the setting of other chronic liver diseases
still remains unknown.
Therefore the aim of the present study was to assess
the value of measuring adiponectin concentrations in
patients with NAFLD (non-alcoholic fatty liver disease)
in comparison with patients with non-metabolic chronic
liver diseases and patients with cirrhosis.
MATERIALS AND METHODS
Study design and patients
From 1 January 2006 to 31 December 2007, patients
referred to a tertiary liver outpatient clinic were
enrolled prospectively after signing an informed consent
form and following the approval by the local ethics
committee. For each patient, the following information
was collected: age, BMI, diagnosis, serum fasting levels of
TGs, bile acids, hyaluronate, aminotransferases, glucose
and insulin, transient elastography, measured using
FibroScan®, co-morbidities and current medication.
We assigned all patients to one of three groups: (i)
NAFLD, (ii) chronic liver diseases other than NAFLD
(including viral hepatitis, n=71; autoimmune disease,
n=18; alcohol-induced liver disease, n=3; or elevated
liver enzymes of unknown origin, n=31) and (iii)
cirrhosis (whatever its cause). The allocation was based
on the following criteria: cirrhosis, biopsy-proven or
complications of cirrhosis (oesophageal varices, ascites);
and NAFLD, biopsy-proven or clinical presentation
[adiposity, hyperlipidaemia in combination with elevated
ALT (alanine aminotransferase) after exclusion of other
liver disease and hyperechogenic appearance of liver
parenchyma at sonography].
Adiponectinserumlevelsof20healthycontrolsubjects
weremeasuredfrom1January2006to31December2006.
Prior to measurement, all control subjects underwent
a detailed interview, a clinical examination, and serum
CRP (C-reactive protein), creatinine and albumin were
measured to exclude chronic diseases. At the time of
bloodsampling,allcontrolswerefreeofpharmacological
treatments.
Biochemical assays
Fasting serum adiponectin levels were determined with a
human colorimetric sandwich ELISA kit (Mediagnost).
Insulin levels were quantiﬁed by electrochemilumines-
cence. Hyaluronate was determined using the Corgenix
protein binding assay. Bile acids were monitored
enzymatically using the reagents from Trinity Biotech
on a Mira plus chemistry analyser (Roche Diagnostics).
Brieﬂy, bile acids were ﬁrst oxidized to 3-oxo bile acids
in the reaction catalysed by 3α-HSD (3α-hydroxysteroid
dehydrogenase). During this oxidative reaction, an
equimolar quantity of NAD [11] is reduced to NADH.
The NADH is subsequently oxidized to NAD with
concomitant reductionofNBT(NitroBlueTetrazolium)
salttoformazanbythecatalyticactionofdiaphorase.The
formazan has an absorbance maximum at 530 nm. The
intensity of the colour produced is directly proportional
to the concentration of the bile acids in the sample.
Glucose,TGs,ALTandAST(aspartateaminotransferase)
weredeterminedintheClinicalChemistryLaboratoryof
theInselpital(Bern,Switzerland).HOMA(homoeostasis
model assessment) scores were calculated with the
HOMA index formula [insulin (μ-units/ml)×glucose
(mmol/l)/22.5]. All measurements were made according
to the manufacturer’s protocol. Elastography was
assessedusingFibroScan® byanexperiencedinvestigator.
Statistical analysis
Q-Q (quantitle-quantile) plots were made to conﬁrm
the parametric distribution of the data. Pair-wise
comparisons of the serum concentrations of adiponectin
with AST, ALT, bile acids, hyaluronate, insulin, glucose,
TG, elastography, ﬁbrosis and HOMA index were
performed by correlation matrices. One-way ANOVA,
χ2 tests and independent Student’s t tests were used to
compare the groups. Data were adjusted for age, gender
and BMI using ANCOVA (analysis of co-variance).
All tests were performed using SAS/STAT or Prism5
Software.
RESULTS
A total of 232 patients (136 men and 96 women) and 20
healthy controls (11 men and 9 women) were included:
64 patients with NAFLD, 123 with other chronic liver
disease and 45 with cirrhosis. Of these, 101 patients had
a liver biopsy (40 with NAFLD, 42 with other chronic
liver disease and 19 with cirrhosis). The anthropometric
data are shown in Table 1 and Supplementary Figure S1
(at http://www.clinsci.org/cs/119/cs1190431add.htm).
ANOVA revealed differences between the patient
groups for adiponectin, BMI, transient elastography,
AST, glucose, insulin, HOMA index, bile acids, TGs
and hyaluronic acids, whereas there was no signiﬁcant
difference for ALT (Table 1). BMI and the HOMA
index were signiﬁcantly higher in patients with NAFLD
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Table 1 Anthropometric data and laboratory values of the three different patient groups and the controls
Values are presented as means. P values were obtained with one-way ANOVA and χ2 tests comparing the three patient groups.
Patients with
Characteristic Cirrhosis (n=45) NAFLD (n=64) Other liver disease (n=123) Controls (n=20) P value
Gender (n) (male/female) 29/16 49/15 58/65 11/9 0.001
Diabetes/treated (n) 7/6 15/13 5/3 − 0.39
Age (years) 57 52 49 37 0.01
BMI (kg/m2) 28.1 30.5 25.8 23.7 <0.001
ALT (units/l) 59.1 73.2 61.2 − 0.12
AST (units/l) 82.9 51.6 50.3 − <0.001
Bile acids (μmol/l) 68.7 23.8 24.7 − <0.001
Hyaluronate (μg/l) 340 41 47 − <0.001
FibroScan® (kPa) 40.3 8.9 7.7 − <0.001
TG (mmol/l) 1.5 2.4 1.2 − 0.001
Insulin (μ-units/ml) 16.4 18.8 8.4 − <0.001
Glucose (mmol/l) 5.8 6.0 5.0 − <0.001
HOMA 3.6 5.1 2.0 − <0.001
Adiponectin (μg/ml) 18.6 4.8 10.4 9.1 <0.001
(P<0.001), whereas hyaluronate, bile acids and
elastography values were signiﬁcantly higher in patients
with cirrhosis (P<0.001).
Fasting serum adiponectin levels were higher in
patients with cirrhosis compared with patients without
cirrhosis (18.6+ −14.5 compared with 8.4+ −6.1 μg/ml
respectively; P<0.0001; Figure 1A). This difference
remained after adjustment for age, gender and BMI
(P=0.0001). In patients with NAFLD, serum adipo-
nectin levels were signiﬁcantly decreased compared with
those with other liver disease (4.8+ −3.5 compared with
10.4+ −6.3 μg/ml respectively; P<0.0001; Figure 1B).
Separating patients with simple steatosis from patients
with NASH did not reveal a signiﬁcant difference
in serum adiponectin levels (Supplementary Figure
S2 at http://www.clinsci.org/cs/119/cs1190431add.htm),
and patients with NAFLD had decreased levels
independently of age, gender or BMI (P=0.0001).
There was a signiﬁcant correlation between serum
adiponectin levels and bile acids (r=0.51, P<0.001),
serum hyaluronate levels (r=0.52, P<0.001) and
elastography values (r=0.45, P<0.001), consistent with
the higher adiponectin levels observed in patients
with cirrhosis (Figure 2).
Serum adiponectin levels signiﬁcantly correlated with
body weight and serum TG levels (P<0.001) (Figure 3).
Analysis according to gender revealed that adiponectin
levels correlated with body weight in men and women
(r=−0.22,P=0.024comparedwithr=−0.29,P=0.004
respectively), whereas the correlation with BMI was lost
in men (r=−0.34, P<0.001 in women compared with
P=0.22 in men). No correlation was observed
with markers of glucose metabolism (fasting glucose,
insulin or HOMA index; results not shown).
Our healthy controls had adiponectin levels with the
typical gender- and BMI-speciﬁc variations that have
beenreportedpreviously([10]andSupplementaryFigure
S3 at http://www.clinsci.org/cs/119/cs1190431add.htm)
and that are in accordance with the validation study per-
formed in 226 healthy subjects by Professor J. Kratzsch
(Institute of Laboratory Medicine, Clinical Chemistry
and Molecular Diagnostics, University of Leipzig,
Leipzig, Germany) published in the ELISA kit manufac-
turer’s protocol (http://search.cosmobio.co.jp/cosmo_
search_p/search_gate2/docs/MDA_/E09.20081120.pdf).
DISCUSSION
The main ﬁndings of the present study are that BMI-,
gender- and age-corrected serum adiponectin levels are
low in patients with NAFLD, but are elevated in patients
with cirrhosis. This has implications for its interpretation
in the clinic.
Serum adiponectin levels are signiﬁcantly lower in
patientswithNAFLDcomparedwithpatientswithother
chronic liver diseases. NAFLD is viewed as the hepatic
manifestationofthemetabolicsyndromeandadiponectin
measurement can help to identify patients with this
condition. Others have suggested that the sensitivity
of serum adiponectin levels in the diagnosis of NASH
was 68%, which was higher than for any other marker,
while its speciﬁcity was 79% [13]. Adiponectin prevents
steatosis by stimulating mitochondrial β-oxidation via
activation of AMPK (AMP-activated protein kinase) and
PPAR-α (peroxisome-proliferator-activated receptor-α)
and down-regulation of SREBP-1c (sterol-regulatory-
element-binding protein-1c), a master regulator of fatty
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Figure 1 Adiponectin levels in the study groups
Adiponectin levels were signiﬁcantly increased in patients with liver cirrhosis
compared with patients without cirrhosis (non-cirrhosis) (A), whereas they were
decreased in patients with NAFLD (B). Serum adiponectin levels are presented
as means+S.D. *P <0.001 as determined by ANCOVA with adjustment for age,
gender and BMI.
acid synthesis [14,15]. Moreover, adiponectin attenuates
oxidative stress, pro-inﬂammatory cytokine production
and ameliorates liver ﬁbrosis via suppression of activated
hepatic stellate cell function. Therefore low circulating
levels of adiponectin may be associated with the
development of NASH in patients with steatosis and in
the progression of NASH towards cirrhosis. Outside the
liver,decreasedadiponectinconcentrationsareassociated
not only with increased coronary risk, but also with the
progression of atherosclerosis in coronary vessels [11].
Thus adiponectin levels have a strong impact on disease-
related morbidity and mortality in a variety of diseases
associated with the metabolic syndrome.
Importantly, we found that adiponectin levels
correlatedwellwithmarkersofhepaticﬁbrosis,including
serum fasting bile acids, hyaluronate and transient
elastography, even in the presence of elevated BMI.
It has been shown that serum bile acids are elevated
in patients with NASH and increase with disease
progression [16]. We demonstrated that adiponectin
levels correlate signiﬁcantly with serum bile acids
and thus accompany disease progression. One may
speculate that this increase is due to less clearance of
Figure 2 Correlation of serum adiponectin with bile acids,
hyaluronate and elastography
Serum adiponectin levels were signiﬁcantly correlated with bile acids, hyaluronate
and elastography. Patients from all groups were considered together.
adiponectin in the liver of patients with cirrhosis. In
fact, high adiponectin levels after bile-duct ligation in
mice and in human bile from patients with cholestasis
suggest that biliary secretion is involved in adiponectin
clearance [17]. However, a recent study has shown
that the serum adiponectin concentration was negatively
associated with higher levels of ﬁbrosis and that low
adiponectin levels are an independent risk factor for
advanced ﬁbrosis in patients with NAFLD [18]. Thus,
in interpreting adiponectin levels in patients with
NAFLD, one has to take into account the stage of
the disease: if characteristically low in early stages, it
will increase with the progression of the disease to
actually be elevated in patients with cirrhosis. In our
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Figure 3 Correlation of serum adiponectin with body
weight and TG
Serum adiponectin signiﬁcantly correlates with body weight and serum TG
(triglyceride) levels. Patients of all groups were considered together.
patient cohort, patients with NASH-induced cirrhosis
had adiponectin concentrations similar to patients with
cirrhosis of other causes (see Supplementary Figure S4 at
http://www.clinsci.org/cs/119/cs1190431add.htm). This
isinlinewiththeobservationthatpatientswithNAFLD-
induced cirrhosis frequently lose the histological features
of NASH, such as steatosis.
Moreover, our present ﬁndings show a correlation
between serum adiponectin levels and the body weight
of patients. It has been shown that plasma adiponectin
levels are lower in obese than in non-obese subjects, and
weight reduction signiﬁcantly raises plasma adiponectin
levels [19,20]. Treating patients with NASH with vitamin
E and UDCA (ursodeoxycholic acid) also signiﬁcantly
increased serum adiponectin levels [21]. Therefore
adiponectin is the only fat protein that shows down-
regulation in relation to weight gain, and it has been
proposed that an accumulation of visceral fat might
produce inhibiting factors for adiponectin synthesis or
secretion [22]. Adiponectin levels signiﬁcantly correlated
with serum TG concentrations, another important
parameter of the metabolic syndrome.
Thus serum adiponectin levels not only accompany
markers of hepatic ﬁbrosis, but also correlate with
parameters involved in metabolic disease.
The present study is limited by its relatively small
number of patients; many of them did not have a liver
biopsy. However, it is a cross-sectional study, which
represents the real situation of an outpatient clinic and
showsthevalueofadiponectinmonitoringinthissetting.
Cohortstudieswillbenecessarytodocumenttheincrease
incirculatinglevelsofadiponectininpatientswithNASH
when they develop cirrhosis. In our group of patients
with NAFLD, we observed a male predominance (49
men/15 female). Adiponectin levels are known to be
lower in males compared with females; however, analysis
of the data adjusted for gender revealed no signiﬁcant
difference in the reduction in adiponectin levels in this
patient subgroup.
In conclusion, adiponectin levels show a two-phase
distribution in liver disease. In steatosis and NASH,
adiponectin levels are low, in keeping with a proposed
protective effect in these conditions and suggesting
elevation of adiponectin as a desirable therapeutic
target in NAFLD. In advanced liver disease, however,
adiponectin is elevated. Therefore in the context of
negative elastography, and serum hyluronate and bile
acids, abnormally low adiponectin may be a good
additional marker for NAFLD.
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Figure S1 Distribution of anthropometric data and laboratory values in the three patient groups
The values shown are those presented in Table 1 of the main text.
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Figure S2 Serum adiponectin levels in patients with NAFLD
and other chronic liver disease
Values are presented as means+S.D. No signiﬁcant difference (P =0.62) was
observed between patients with simple steatosis (n=14) and NASH (n=52).
*P <0.001.
Figure S3 Serum adiponectin levels of healthy control
subjects reﬂecting the typical gender- and BMI-related
alterations
Values are presented as means+S.D.
Received 4 January 2010/1 June 2010; accepted 4 June 2010
Published as Immediate Publication 4 June 2010, doi:10.1042/CS20100008
Figure S4 Serum adiponectin levels in patients with liver
cirrhosis stratiﬁed by its origin
Values are presented as means+S.D. all, n=45; NASH-related, n=7;
Non-NASH, n=38.
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